1957

Developed and launched “Norumo”,
the first product

1971
1972

Launched “Wonbi-D”, the ginseng nutritious tonic
Exported “Wonbi-D” to Japan

1986

Established the Central Research Institute

1992~1995
1997. 12
1998. 11

Clinical trial for Ilaprazole
Obtained the U.S. substance patent for Ilaprazole
Obtained the Korean substance patent for Ilaprazole

2001. 12

2007. 05

2007. 10


2007. 12

2008. 07

2008. 11

2008. 12




2009. 03
2009. 07
2009. 12
2011. 08

2012. 07

2012. 01

2014. 02



2014. 05

2014. 06


2014. 07




2014. 08

2015. 01


2015. 02




2015. 05


2015. 06



2015. 07

2015. 10



2015. 12



2016. 02

2016. 02

2016. 03


2016. 05


2016. 05

2016. 05


2016. 05



2016. 06


2016. 07

Entered into the license agreement with
China’s Livzon Pharmaceutical for Ilaprazole
Multinational phase 3 clinical trial for Ilaprazole
(6 South East Asian countries)
Completed the phase 2 clinical trial for Ilaprazole’s effect on reflux esophagitis in the United States
Obtained the approval of the Ilaprazole sale in China
Started the phase 1 clinical trial for radotinib (IY5511)
Obtained the approval of Ilaprazole (the nation’s 14th new indigenous drug)
Established the SIS Immunology Research Center
(Jointly with Sook-myung Women's University -Ilyang Pharmaceutical - Samsung Seoul
Hospital),Started the research into new cytokine
and new peptide
Obtained the U.S. patent for radotinib
Started the phase 2 clinical trial for radotinib
Launched the Ilaprazole (Noltec tab) (in Korea)
Started the phase 3 clinical trial for radotinib,
the primary treatment drug
Ilyang submitted the influenza vaccine IND
and phase 1 clinical trial IRB
Obtained the approval of radotinib(the nation’s
18th new indigenous drug: Supect)
Government held “Transgovernmental Enterprise
for Pandemic Influenza in Korea(TEPIK)” Contest In the Final Selection, a New Influenza Vaccine,
H7N9 form, Selected as Research Project Respiratory Syncytial Virus(RSV) Treatment Substance Developed
Supect, the Result of 24 month of Clinical Phase II Presented at the 19^th EHA(European Hematology Association)
General Hospital of Beijing, Presented a Paper of Noltec
Noltec, First Time Published on Global Medical Journal “AP&T”
MOU Signed with College of Medicine KOREA University Research and Institute for Industry Cooperation
Initiation of clinical trial phase 1/2a for quadrivalent inactivated Influenza Vaccine (egg-based)
SUPECT, early completion of multi-national/multi-center clinical trial phase 3
Approved market authorization for IL-YANG Flu Vaccine Vial INJ.(Trivalent inactivated influenza vaccine)
SUPECT, Clinical trial result presented at Autumn conference of the Korean Society of Hematology(KSH)
“SUPECT” validated as a potential treatment for Acute Myeloid Leukemia(AML)
Candidate material for New Drug confirms efficacy on “Ebola Virus”
Discover potential “MERS Virus” treatment substance
Initiated Phase III Clinical trial for Quadrivalent Influenza Vaccine
Super leukemia treatment SUPECT approved for 1st line treatment
SUPECT, Orally presented its Final Phase III Clinical Trial Results at
2015 American Society of Hematology (ASH) Annual Meeting
SUPECT, Launching Ceremony for 1st Line Therapy
IL-YANG PHARM, MOU signed with Gyeongbuk Institute for Bio Industry
SUPECT, Presented Phase III Clinical Trial Results at 2016 Highlight of ASH in Asia-Pacific (2016 HOA)
IL-YANG, entered MOU with Cha Vaccine R&D Center for cooperate R&D of Flu Vaccines and other New Vaccines.
Discovered an effective material for ‘Zika’ and ‘MERS’ virus treatment.
Development of ‘Prion Diseases Treatment’ has been selected as research project of Ministry of Health and Welfare.
New influenza vaccine research project finally selected as governments’ “Infectious diseases crisis management technology development“ contest.
‘H7N9 Vaccine’ Avian Influenza vaccine, presented at 35th American Society for Virology (ASV) Annual Meeting.
Development of MERS virus treatment, selected as governmental research project